Journal of Critical Care has published positive results from AdrenoMed's Phase II AdrenOSS-2 trial, showing enibarcimab improved organ function and reduced 28-day mortality in septic shock patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.